Droncit (praziquantel tablets) 23 Feline Cestocide

Company: Elanco US

Droncit (praziquantel tablets) 23 Feline Cestocide Caution

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Each Tablet Contains 23 mg Praziquantel

Description

Droncit (praziquantel tablets) 23 Feline Cestocide are sized for easy oral administration to either adult cats or kittens. The tablets may be crumbled and mixed with the feed.

Droncit (praziquantel tablets) 23 Feline Cestocide Indications

Droncit (praziquantel tablets) 23 Feline Cestocide are indicated for the removal of the following feline cestodes: Dipylidium caninum and Taenia taeniaeformis.

Contraindications

There are no known contraindications to the use of praziquantel in cats.

ACTION: Droncit (praziquantel tablets) is absorbed, metabolized in the liver and excreted in the bile. Upon entering the digestive tract from the bile, cestocidal activity is exhibited.¹

Following exposure to praziquantel, the tapeworm loses its ability to resist digestion by the mammalian host. Because of this, whole tapeworms, including the scolex, are very rarely passed after administration of praziquantel. In many instances only disintegrated and partially digested pieces of tapeworms will be seen in the stool. The majority of tapeworms killed are digested and are not found in the feces.

USE DIRECTIONS: Droncit (praziquantel tablets) 23 Feline Cestocide may be administered directly per os or crumbled and mixed with the feed. The recommended dosage of praziquantel varies according to body weight. Smaller animals require a relatively larger dosage because of their higher metabolic rate. The optimum dose for each individual animal will be achieved by utilizing the following dosage schedule:

Cats and Kittens*

*Not intended for use in kittens less than 6 weeks of age.

FASTING: The recommended dosage of praziquantel is not affected by the presence or absence of food in the gastrointestinal tract, therefore, FASTING IS NEITHER NECESSARY NOR RECOMMENDED.

RETREATMENT: For those animals maintained on premises where reinfections are likely to occur, clients should be instructed in the steps necessary to prevent reinfection; otherwise, retreatment may be necessary. This is especially true in cases of Dipylidium caninum infections where reinfection is almost certain to occur if fleas are not removed from the animal and its environment.

ANIMAL SAFETY: The safety index has been derived from controlled safety evaluations, clinical trials and prior approved use in foreign countries.

Dosages of 5 times the labeled rate at 14 day intervals to cats as young as 5 1/2 weeks did not produce clinical signs of toxicity. No significant clinical chemistry, hematological, or histopathological changes occurred. Symptoms of gross overdosage include vomition, salivation, diarrhea and depression.

PREGNANCY: Droncit (praziquantel tablets) has been tested in breeding and pregnant cats. No adverse effects were noted.

Adverse Reactions

One instance of diarrhea and one of salivation (1.5%) were reported during the field trials in which 135 cats were administered Droncit (praziquantel tablets) 23 Feline Cestocide.

For product questions, to report adverse reactions, or for a copy of the Safety Data Sheet (SDS), call Elanco Product & Veterinary Support at 888-545-5973.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

Warning

Keep out of the reach of children. Not for human use.

For customer service or to obtain product information, including Safety Data Sheet, call 1-800-633-3796.

Storage

Store at less than or equal to 25°C (77°F)

How Supplied

Bottle of 50 and 150 scored tablets.

Each scored tablet contains 23 mg praziquantel.

- 50 Tablets

- 150 Tablets

References

¹ Andrews, P. Pharmacokinetic Studies with Droncit in Animals Using a Biological Assay. Veterinary Medical Review 2/76: 154-165.

Manufactured for:

Elanco US Inc., Greenfield, IN 46140 U.S.A.

Made in China

Droncit, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2022 Elanco or its affiliates.

Approved by FDA under NADA # 111-798

Revised: March 2022

90207939_PA600229X

W1b

CPN: 1131159.0